Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 114

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 114
---
. S. trials. We are seeking to develop the Alpha DaRT technology by conducting feasibility studies in other indications and    
  then generating potentially registrational data in other such indications, such as pancreas, brain and prostate cancers, as well as in  
  patients with metastatic cancer. As of December 31, 2024, we have fourteen clinical trials ongoing worldwide. We are also discussing    
  with the FDA our interest in initiating additional clinical studies in the U. S. during the course of 2025.                             
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Continue to evaluate the                                                                                                                          
  potential systemic immune response generated by the Alpha DaRT, particularly in combination with immunotherapies. We have conducted               
  extensive pre-clinical studies focused on the combination of Alpha DaRT with immunomodulators, which have demonstrated encouraging anti-tumor     
  immune responses. By combining our Alpha DaRT technology with systemic therapies, we seek to harness the Alpha DaRT’s potential                   
  immunogenic activity and trigger an immune response to detect and destroy metastatic cancers. In January 2025 we first presented interim          
  data from our combination study of Alpha DaRT and pembrolizumab (Keytruda) for the treatment of SCC of the head and neck, or HNSCC, in            
  Israel, demonstrating a 75% objective response rate and 37.5% complete response rate in the first eight patients treated in the study             
  as of January 9, 2025. We are exploring the possibility of conducting a similar clinical trial in the U. S. In addition, we conduct pre-clinical  
  experiments in our own radioactive pre-clinical laboratory at our headquarters in Jerusalem, Israel to further explore potential combination      
  therapies with Alpha DaRT.                                                                                                                        
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Expand our independent manufacturing capabilities across strategic geographical                                                                
  regions. We are establishing production sites in key regions around the world in order to supply sufficient radioactive sources with fast,     
  reliable and cost-efficient delivery to our global clinical trials and core markets where we may seek additional marketing authorizations      
  (which, for the avoidance of doubt, includes ‘certifications’ as used in this Annual Report with respect to applicable jurisdictions).         
  We currently operate two manufacturing plants: one facility located in Jerusalem, Israel, where we